The New York Entrepreneur

Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs 

Read Time:9 Second

The results come as Bristol Myers moves to cut $1.5 billion in costs by 2025 and reinvest that money into key drug brands and research and development programs.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Liquidation of crowded trades so far is healthy — but these levels must hold, says Bank of America
Next post Warner Bros. Discovery is counting on deregulation to unlock media deals — if there’s even appetite